



## LA Control Plasma Weak

REF SC082K

C1 6 x 1 mL

Weak positive human plasma for the quality control of Lupus Anticoagulant clotting assays.

English, Last revision: 07-2023

### INTENDED USE:

LA Control Plasma Weak Kit is a set of lyophilized quality control plasmas, weak positive, for use in Lupus Anticoagulant *in vitro* clotting assays. This kit is optimized for being used with the HEMOCLOT™ LA-S and HEMOCLOT™ LA-C assays (CK090K/CK091K/CK094K).

### SUMMARY AND EXPLANATION:

"Lupus anticoagulant" is associated with numerous clinical states including e.g. lupus, thrombosis, foetal loss...and must usually be confirmed from multiple assays. These control plasmas are then proposed for the quality control of Lupus anticoagulant detection in plasma using *in vitro* clotting assays, especially HEMOCLOT™ LA-S and HEMOCLOT™ LA-C assays (CK090K/CK091K/CK094K).

### REAGENTS:

The LA Control Plasma Weak kit contains 6 vials of 1 mL of weak positive human plasma for lupus anticoagulant.

**C1** LA Control Plasma Weak. Human plasma, lyophilized.  
6 vials of 1 mL.

For the assay, refer to indicative normalized ratio on the flyer provided in the kit used.

### WARNINGS AND PRECAUTIONS:

- Control plasmas contain stabilizers.
- Each pouch of human plasma used for kit preparation was obtained from healthy donors. Each plasma used was screened for the presence of the HBS antigen, of anti-HIV1, anti-HIV2 and anti-HCV antibodies, using approved methods, and found to be negative. Nevertheless, no tests can totally exclude the presence of infectious agents. For this reason, every precaution required for the use of potentially infectious products should be taken when handling and disposing of plasma.
- Waste should be disposed of in accordance with applicable local regulations.
- Handle the reagents with care to avoid contamination during use. If possible, avoid reagent evaporation during use by limiting the liquid-air exchange surface. Evaporation reduces the reagent's stability in the analyzer.
- To ensure reagent stability, seal the vials after use with their respective caps, or close the plastic micro-containers into which the plasmas may have been transferred, depending on the protocol used.
- Aging studies, conducted over a 3-week period at 30°C, show that the reagents can be shipped at room temperature over a short period of time, without degradation.
- Incubating the reconstituted vials at room temperature allows stabilizing the reagents, and obtaining a homogeneous reactivity.
- It is recommended to homogenize each vial before use, in order to have a good reproducibility, all the time.
- For *in vitro* diagnostic use.

### REAGENT PREPARATION AND STABILITY:

The reagents are lyophilized under vacuum in their vials. To avoid any product loss when opening the vial of lyophilized reagents, gently remove the freeze-drying stopper.

#### **Controls:**

Reconstitute each vial with exactly 1 mL of distilled water, shake thoroughly for complete homogenization, let the reagent stabilize for 30 min at room temperature (18-25°C); while shaking the vial from time to time. Homogenize before each use.

Reagent stability after reconstitution, free from any contamination or evaporation, and stored in the original vial, is of:

- 24 hours at 2-8°C.
- 8 hours at room temperature (18-25°C).
- 7 days frozen at -20°C or below\*

\*Thaw once as rapidly as possible at 37°C, adapt duration to the volume of reagent. The stability of the thawed reagent should be verified in the working conditions of the user laboratory.

### STORAGE CONDITIONS:

Unopened reagents should be stored at 2-8°C in their original packaging. Under these conditions, they can be used until the expiry date printed on the kit.

### REAGENTS AND MATERIALS REQUIRED BUT NOT PROVIDED:

#### **Reagents:**

- Distilled water.
- HEMOCLOT™ LA-S and HEMOCLOT™ LA-C assays (CK090K / CK091K / CK094K).

#### **Materials:**

- Calibrated pipettes.

### TRACEABILITY:

Normal frozen plasma pool is used for the determination of normalized ratio.

### PROPERTIES:

The LA Control Plasma Weak is proposed for the quality control of lupus anticoagulant assays using HEMOCLOT™ LA-S and HEMOCLOT™ LA-C kit (CK090K/CK091K/CK094K).

It allows validating the homogeneous reactivity from run to run, when using a same lot of reagents. Quality controls must be included in each series, as per good laboratory practice, in order to validate generated results.

If controls are out of the acceptance range, the test series must be invalidated, and the assay should be rerun. Check all the components of the test system, before repeating the assay.

If used with assays or instruments from other manufacturers, measured values can vary according to the assay reactivity and its standardization.

Each laboratory must then determine and validate the appropriateness of using this control and expected range in its specific assay conditions.

### LIMITATIONS:

- Like all lyophilized plasmas, control plasmas are more or less turbid once resuspended. This turbidity is mainly due to plasma lipids that, after freeze-drying, become "less" soluble and may form a slight deposit.
- Any plasma displaying a coagulum or showing signs of bacterial or fungal contamination must be rejected.
- If the controls are used under measurement conditions other than those validated by HYPHEN BioMed, the test results may vary. The laboratory is responsible for validating the use of these controls in its own analytical system.
- Control plasmas are subjected to the limitations of the assay system.

### REFERENCES:

1. Devreese *et al.* Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection and interpretation. *J Thromb Haemost.* 2020.
2. CLSI Document H60-A: "Laboratory Testing for the Lupus Anticoagulant; Approved Guideline". 2014
3. CLSI Document H21-A5: "Collection, transport, and processing of blood specimens for testing plasma-based coagulation assays and molecular hemostasis assays; approved guideline". 2008.
4. Rauch J. *et al.* Distinguishing lupus anticoagulants from antifactor antibodies using hexagonal phase II phospholipids *Thromb Haemost.* 1989.

### SYMBOLS:

Symbols used and signs listed in the ISO 15223-1 standard, see Symbol definitions document.

Changes compared to the previous version.